Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433960 | 0.97 | CRHR1 (0.41) | CRHR1FYN | |
| SCHEMBL5441312 | 0.94 | CRHR1 (0.43) | CRHR1FYN | |
| SCHEMBL5436388 | 0.89 | CRHR1 (0.38) | CRHR1FYN | |
| SCHEMBL5429581 | 0.88 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5437665 | 0.86 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5434388 | 0.86 | CRHR1 (0.35) | CRHR1FYN | |
| SCHEMBL5434105 | 0.85 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5443222 | 0.85 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL5443557 | 0.84 | CRHR1 (0.44) | CRHR1FYN | |
| SCHEMBL5429674 | 0.84 | CRHR1 (0.48) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885FYN 4047/4885 |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885FYN 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.